Novel use of peptide compounds for treating amyotrophic lateral sclerosis

Details for Australian Patent Application No. 2005251459 (hide)

Owner Schwarz Pharma AG

Inventors Stohr, Thomas

Agent Davies Collison Cave

Pub. Number AU-A-2005251459

PCT Pub. Number WO2005/120476

Priority 60/578,063 09.06.04 US; 04013636.8 09.06.04 EP

Filing date 8 June 2005

Wipo publication date 22 December 2005

International Classifications

A61K 31/165 (2006.01) - having aromatic rings, e.g. colchicine, atenolol, progabide

A61K 31/16 (2006.01) - Amides, e.g. hydroxamic acids

Event Publications

7 December 2006 PCT application entered the National Phase

  PCT publication WO2005/120476 Priority application(s): WO2005/120476

13 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005251461-1-`(3r)-amino-4-(2-fluoro-phenyl)-butyl !-pyrrolidine-(2r)-carboxilic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase IV (DPP-IV) inhibitors for the treatment of Type 2 diabetes mellitus

2005251456-Apparatus and method for reducing interference